Company Encyclopedia
View More
name
Beilu Pharma
300016.SZ
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as well as iodine-based agents comprising iohexol, ioversol, iodixanol, iopromide, and iopamidol, as well as oral anti-diabetic drugs.
3.159 T
300016.SZMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking60/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.72%C
    • Profit Margin2.97%C
    • Gross Margin44.32%B
  • Growth ScoreB
    • Revenue YoY16.06%B
    • Net Profit YoY167.81%A
    • Total Assets YoY7.01%B
    • Net Assets YoY28.19%A
  • Cash ScoreA
    • Cash Flow Margin3369.36%A
    • OCF YoY16.06%B
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreB
    • Gearing Ratio26.47%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Beilu Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 44.1769 million yuan, an increase of 81.10%

    Beilu Pharma released its third-quarter report for 2025, with operating revenue of 873 million yuan in the first three quarters, a year-on-year increase of 19.59%. The net profit attributable to the parent company was 44.1769 million yuan, an increase of 81.10%; the net profit excluding non-recurring gains and losses was 33.6758 million yuan, an increase of 33.53%. The basic earnings per share were 0.087 yuan

    Zhitong·
    SZ
    300016
    +1.61%
    Zhitong·
    SZ
    300016
    +1.61%

    Beilu Pharma plans to raise no more than 300 million yuan through a simplified procedure for a private placement

    Beilu Pharma plans to issue shares to specific targets through a simplified procedure, raising no more than 300 million yuan. This issuance will be directed at no more than 35 specific targets, with the issuance price not lower than 80% of the average price of the 20 trading days prior to the pricing benchmark date. The raised funds will be used for the production workshop and intelligent comprehensive warehouse project of Luzhibao Pharmaceutical, technological transformation projects, and to supplement working capital

    Zhitong·
    SZ
    300016
    +1.61%
    Zhitong·
    SZ
    300016
    +1.61%

    Beilu Pharma: Haichang Pharmaceutical has obtained GMP certification from the Brazilian National Health Surveillance Agency

    According to the Zhitong Finance APP, Beilu Pharma announced that its holding subsidiary Zhejiang Haichang Pharmaceutical Co., Ltd. (referred to as "Haichang Pharmaceutical") has officially passed the GMP (Good Manufacturing Practice) certification by the Brazilian National Health Surveillance Agency (referred to as "Brazil ANVISA")

    Zhitong·
    SZ
    300016
    +1.61%
    Zhitong·
    SZ
    300016
    +1.61%

    The leading stocks in the brain-computer interface concept continue to strengthen, with 6 stocks receiving institutional research 5 times or more

    As of August 15, brain-computer interface concept stocks have averaged a 48.67% increase, with 4 stocks doubling in value, including Innovative Medical, Hanwei Electronics, Xiangyu Medical, and APON. Since the beginning of this year, a total of 27 brain-computer interface concept stocks have been investigated by institutions, with 6 stocks being researched 5 times or more, namely Beilu Pharma, Xiangyu Medical, Tom Cat, Zhongke Information, Shengshi Technology, and Hanwei Electronics. Beilu Pharma was investigated 22 times, ranking first

    Wallstreetcn·
    SZ
    300007
    +3.18%
    SZ
    300753
    +1.61%
    SZ
    300016
    +1.61%
    Wallstreetcn·
    SZ
    300007
    +3.18%
    SZ
    300753
    +1.61%
    SZ
    300016
    +1.61%

    Beilu Pharma: Iodinated Methylpyrrolidone Chemical Raw Material Approved for Market Launch

    Beilu Pharma's subsidiary Zhejiang Haichang Pharmaceutical recently received approval from the National Medical Products Administration for the market launch of Iopamidol chemical raw materials. Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and angiography, particularly suitable for patients with renal insufficiency and high-risk patients. Due to its excellent imaging effect and lower side effects, it has become one of the preferred contrast agents in clinical practice

    Zhitong·
    SZ
    300016
    +1.61%
    Zhitong·
    SZ
    300016
    +1.61%
    © 2025 Longbridge｜Disclaimer